

ISIS Pharma - Picture Beyond KYNAMRO - Targeting Other Niche Indications

https://marketpublishers.com/r/I1F2085E6C4EN.html

Date: January 2013

Pages: 7

Price: US\$ 140.00 (Single User License)

ID: I1F2085E6C4EN

Abstracts

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty. Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic delivery of more drugs to the target organs other than liver is the acid test that all antisense/ RNAi focused companies have to pass. ISIS has a robust cash position, valuable IP assets, and success of a few drugs in the current pipeline could accelerate the transformation from a discovery to a pharma company and help it to grow beyond KYNAMRO.



I would like to order

Product name: ISIS Pharma - Picture Beyond KYNAMRO - Targeting Other Niche Indications

Product link: https://marketpublishers.com/r/l1F2085E6C4EN.html

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l1F2085E6C4EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970